‘metacognition, n.’ OED online. Oxford University Press, 2016. Available at: http://www.oed.com/.
2.
MehtaRHPetersonEDCaliffRM. Performance measures have a major effect on cardiovascular outcomes: a review. Am J Med2007; 120: 398–402.
3.
Institute of Medicine. Clinical Practice Guidelines We Can Trust. Washington, DC: The National Academies Press, 2011.
4.
StoneNJRobinsonJGLichtensteinAH, et al.. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol2014; 63: 2889–2934.
5.
Lopez-JimenezFSimhaVThomasRJ, et al.. A summary and critical assessment of the 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: filling the gaps. Mayo Clin Proc2014; 89: 1257–1278.
6.
Lloyd-JonesDMMorrisPB, et al.. Writing Committee. 2016 ACC expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol2016; 68: 92–125.
7.
AndersonTJGrégoireJPearsonGJ, et al.. 2016 Canadian Cardiovascular Society Guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol Epub ahead of print 2016. DOI: 10.1016/j.cjca.2016.07.510.
8.
CampbellAGlassKG. The legal status of clinical and ethics policies, codes, and guidelines in medical practice and research. McGill Law Journal2001; 46: 473–489.
9.
CannonCPBlazingMAGiuglianoRP, et al.. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med2015; 372: 2387–2397.
10.
ThanassoulisGWilliamsKAltobelliKK, et al.. Individualized statin benefit for determining statin eligibility in the primary prevention of cardiovascular disease. Circulation2016; 133: 1574–1581.
11.
SoranHSchofieldJDDurringtonPN. Cholesterol, not just cardiovascular risk, is important in deciding who should receive statin treatment. Eur Heart J2015; 36: 2975–2983.
12.
SoranHAdamSDurringtonPN. Are recent statin recommendations to employ fixed doses and abandon targets effective for treatment of hypercholesterolaemia? Investigation based on NNT. Eur J Prev Cardiol. 36: 586–590.
13.
RobinsonJRayK. Counterpoint: low-density lipoprotein cholesterol targets are not needed in lipid treatment guidelines. Arterioscler, Thromb Vasc Biol2016. DOI: 10.1161/ATVBAHA.116.306887.
14.
RobinsonJGRayK. Moving toward the next paradigm for cardiovascular prevention. Circulation2016; 133: 1533–1536.
